News outlets report on GlaxoSmithKline’s announcement that it will begin to clinically test an Ebola vaccine.

The Hill: Glaxo to start clinical trials for Ebola vaccine
“British drugmaker GlaxoSmithKline will start clinically testing an Ebola vaccine as international health workers struggle to contain an outbreak of the deadly disease. Glaxo will partner with the National Institutes of Health (NIH) to start a Phase I trial, giving the vaccine to a limited number of patients to test its effectiveness, in the next few months…” (Al-Faruque, 8/11).

Reuters: Clinical trial to start soon on GSK Ebola vaccine
“A clinical trial of an experimental vaccine against the deadly Ebola virus is set to start shortly, according to British drugmaker GlaxoSmithKline, which is co-developing the product with U.S. scientists…” (Hirschler, 8/11).